Skip to content
Bomb Report – Lifestyle
Author:
Hemab Therapeutics, Inc.
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
November 4, 2026
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
November 3, 2026
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
September 24, 2026
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
September 17, 2026
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
July 14, 2026
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
July 12, 2026
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
June 26, 2026
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Hemab Therapeutics Reports First Quarter 2026 Financial Results
May 21, 2026